San Francisco-based Twitter’s stock jumped 30 percent to $50.01 in extended trading Tuesday.
Twitter Inc. posted a net loss of $144.6 million, or 24 cents per share, in the April-June period. That compares with a loss of $42.2 million, or 32 cents per share, a year earlier when Twitter was still a private company.
Tyson Foods Inc. (TSN) agreed to sell poultry businesses in Mexico and Brazil for $575 million as the largest U.S. meat producer shrinks its foreign operations and focuses on the expansion of its prepared foods segment.
JBS’s Pilgrim’s Pride Corp. (PPC) unit will acquire the Mexican assets while Sao Paulo-based JBS will buy the Brazilian business, Tyson said today in a statement.
MEDL Mobile Holdings, Inc. – The company has developed 200 apps for iPhone, iPad, Andorid, and ITouch.
Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver.
The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus visit the Company’s website at www.pvct.com